NewLink Genetics Stock Price, News & Analysis (NASDAQ:NLNK)

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

NewLink Genetics Corp (NASDAQ:NLNK) announced its quarterly earnings data on Tuesday, July, 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The biotechnology company earned $0.15 million during the quarter. NewLink Genetics had a negative return on equity of 34.44% and a negative net margin of 6,587.56%. View NewLink Genetics' Earnings History.

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for NewLink Genetics.

2 equities research analysts have issued 1-year price objectives for NewLink Genetics' stock. Their predictions range from $4.00 to $5.00. On average, they anticipate NewLink Genetics' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 147.3% from the stock's current price. View Analyst Price Targets for NewLink Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.

Media coverage about NLNK stock has trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. NewLink Genetics earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for NewLink Genetics.

NewLink Genetics saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 1,216,100 shares, a drop of 18.6% from the July 31st total of 1,493,800 shares. Based on an average daily volume of 358,700 shares, the short-interest ratio is currently 3.4 days. Currently, 4.2% of the company's shares are short sold. View NewLink Genetics' Current Options Chain.

Some companies that are related to NewLink Genetics include Xeris Pharmaceuticals (XERS), CV Sciences (CVSI), ProQR Therapeutics (PRQR), TapImmune (MRKR), Geron (GERN), Seres Therapeutics (MCRB), Clovis Oncology (CLVS), Recro Pharma (REPH), Evofem Biosciences (EVFM), Evelo Biosciences (EVLO), Concert Pharmaceuticals (CNCE), Kalvista Pharmaceuticals (KALV), MannKind (MNKD), NuCana (NCNA) and Aeglea Bio Therapeutics (AGLE).

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Synergy Pharmaceuticals (SGYP), Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Celldex Therapeutics (CLDX), Sarepta Therapeutics (SRPT), SunPower (SPWR), Alibaba Group (BABA), Novavax (NVAX), Opko Health (OPK) and FireEye (FEYE).

NewLink Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (7.85%), Vanguard Group Inc. (3.79%), Connor Clark & Lunn Investment Management Ltd. (1.56%), Acadian Asset Management LLC (1.47%), BlackRock Inc. (1.44%) and Northern Trust Corp (0.89%). Company insiders that own NewLink Genetics stock include Carl W Langren, Ernest Talarico III and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.

NLNK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Panagora Asset Management Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., Parametric Portfolio Associates LLC and Northern Trust Corp. View Insider Buying and Selling for NewLink Genetics.

NLNK stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, Paloma Partners Management Co, Requisite Capital Management LLC, Jane Street Group LLC, Worth Venture Partners LLC and Tower Research Capital LLC TRC . View Insider Buying and Selling for NewLink Genetics.

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NLNK stock can currently be purchased for approximately $1.82.

NewLink Genetics has a market capitalization of $67.90 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.View Additional Information About NewLink Genetics.

The official website for NewLink Genetics is http://www.newlinkgenetics.com/.

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]